Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Accumulated Expenses (2016 - 2025)

AC Immune has reported Accumulated Expenses over the past 11 years, most recently at $10.1 million for Q4 2025.

  • Quarterly Accumulated Expenses fell 26.91% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Dec 2025, down 26.91% year-over-year, with the annual reading at $10.1 million for FY2025, 26.91% down from the prior year.
  • Accumulated Expenses was $10.1 million for Q4 2025 at AC Immune, down from $15.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $18.2 billion in Q4 2021 and troughed at $9.4 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $12.8 million (2025), against an average of $3.4 billion.
  • Year-over-year, Accumulated Expenses soared 147923.32% in 2021 and then crashed 99.95% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $18.2 billion in 2021, then crashed by 99.95% to $9.8 million in 2022, then skyrocketed by 127766.11% to $12.5 billion in 2023, then plummeted by 99.89% to $13.8 million in 2024, then dropped by 26.91% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Accumulated Expenses are $10.1 million (Q4 2025), $15.0 million (Q3 2025), and $13.9 million (Q2 2025).